In HLA-DP4 transgenic mice, the combination of a vaccine composed of citrullinated Vim and ENO1 peptides with granulocyte–macrophage colony-stimulating factor (GM-CSF) and TLR agonists (especially with TLR1/2 agonist) reduced by 10- to 100-fold the dose of vaccine without losing the anti-tumor activity [40]. Here, ENO1 is linked to neoplasm.